Compare UNCY & EPM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNCY | EPM |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.3M | 165.9M |
| IPO Year | 2021 | 1996 |
| Metric | UNCY | EPM |
|---|---|---|
| Price | $8.12 | $4.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $25.67 | $4.83 |
| AVG Volume (30 Days) | ★ 523.7K | 349.3K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 10.08% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $675,000.00 | ★ $43,229,621.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $582.86 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $3.19 |
| 52 Week High | $8.74 | $5.70 |
| Indicator | UNCY | EPM |
|---|---|---|
| Relative Strength Index (RSI) | 57.60 | 43.63 |
| Support Level | $5.95 | $4.18 |
| Resistance Level | $8.54 | $4.74 |
| Average True Range (ATR) | 0.44 | 0.18 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 55.04 | 24.68 |
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.